Literature DB >> 23529706

Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome.

Kim Donalson1, Steve Turner, Lesley Morrison, Päivi Liitti, Christel Nilsson, Howard Cuckle.   

Abstract

OBJECTIVE: The aim of this research was to evaluate the addition of first trimester maternal serum placental growth factor (PlGF) and α-fetoprotein (AFP) to the combined test for Down syndrome and a serum only protocol of PlGF, AFP, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
METHODS: Samples were from 92 Down syndrome cases with 552 matched controls. All women had a combined test at 11-14 weeks gestation. PlGF and AFP were measured and expressed in multiples of the gestation-specific median (MoM), adjusting for maternal weight and smoking status. Multivariate Gaussian modeling was used to predict detection and false-positive rates.
RESULTS: The median PlGF level in the cases was 0.694 MoM and controls 1.000 MoM (p = <0.0001). The corresponding values for AFP were 0.764 MoM and 0.990 MoM (p < 0.0001). Statistical modeling predicted that for a given false-positive rate, the addition of PlGF to the combined test increases the detection rate by 4-7%. For a given detection rate, the false-positive rate could be almost halved. When both PlGF and AFP are used, the detection rate increase is 5-8%. A serum only protocol had a predicted a detection rate of 71% for a false-positive rate of 5%.
CONCLUSIONS: Results suggest a substantial benefit of adding PlGF to the combined test.
© 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529706     DOI: 10.1002/pd.4087

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  5 in total

1.  Down's Syndrome Screening in the First Trimester with Additional Serum Markers: Indian Parameters.

Authors:  Seshandri Suresh; Howard S Cuckle; Sujatha Jagadeesh; Kushagradhi Ghosh; Gayathri Vemavarapu; Tulika Taval; Sudarshan Suresh
Journal:  J Obstet Gynaecol India       Date:  2019-02-11

2.  Predictive performance of a seven-plex antibody array in prenatal screening for Down Syndrome.

Authors:  Jeroen L A Pennings; Sandra Imholz; Ilse Zutt; Maria P H Koster; Jacqueline E Siljee; Annemieke de Vries; Peter C J I Schielen; Wendy Rodenburg
Journal:  Dis Markers       Date:  2015-04-23       Impact factor: 3.434

3.  Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol.

Authors:  Melissa Hill; David Wright; Rebecca Daley; Celine Lewis; Fiona McKay; Sarah Mason; Nicholas Lench; Abigail Howarth; Christopher Boustred; Kitty Lo; Vincent Plagnol; Kevin Spencer; Jane Fisher; Mark Kroese; Stephen Morris; Lyn S Chitty
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-16       Impact factor: 3.007

Review 4.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

Review 5.  Non-Invasive Screening Tools for Down's Syndrome: A Review.

Authors:  Kelly A Sillence; Tracey E Madgett; Llinos A Roberts; Timothy G Overton; Neil D Avent
Journal:  Diagnostics (Basel)       Date:  2013-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.